A 50-Year-Old Man with Hepatitis C and Cirrhosis Needing Liver Transplantation

JAMA

Volumn 290, Issue 24, 2003, Pages 3238-3246

  Hanto, Douglas W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Transplant Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA2B INTERFERON; BASILIXIMAB; CLOTRIMAZOLE; DACLIZUMAB; HEPATITIS A VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2 RECEPTOR ANTIBODY; LACTULOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NADOLOL; PEGINTERFERON; PNEUMOCOCCUS VACCINE; RAPAMYCIN; RIBAVIRIN; SPIRONOLACTONE; URSODEOXYCHOLIC ACID; VITAMIN D; ZALEPLON;

ADULT; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; EPIDEMIOLOGICAL DATA; ESOPHAGUS VARICES; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; PATIENT SCHEDULING; PHYSICAL EXAMINATION; PORTOSYSTEMIC ANASTOMOSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; SODIUM RESTRICTION; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; VACCINATION;

EID: 0345802947     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.24.3238     Document Type: Conference Paper

References (71)

1. Moore FD, Wheeler HB, Demissianos HV, et al. Experimental whole organ transplantation of the liver and of the spleen. Ann Surg. 1960;152:374-387.
2. Starzl TE, Kaupp AH Jr, Brock DR. Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet. 1960;111:733-743.
3. Starzl TE, Marchioro TL, Von Kaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 1963;117:659-676.
4. Starzl TE, Groth CG, Brettschneider L. Orthotopic homotransplantations of the human liver. Ann Surg. 1968;168:392-415.
5. Starzl TE, Klintmalm G, Porter KA, Iwatsuki S, Schroter GPJ. Liver transplantation with use of cyclosporine A and prednisone. N Engl J Med. 1981;305:266-269.
6. Kalayoglu M, Stratta RJ, Hoffmann RM, et al. Extended preservation of the liver for clinical transplantation. Lancet. 1988;1:617-619.
7. Broelsch CE, Whitington PF, Emond JC, et al. Liver transplantation in children from living related donors: surgical techniques and results. Ann Surg. 1991;214:428-439.
8. Wachs M, Bak TE, Karrer FM, et al. Adult living donor liver transplantation using a right hepatic lobe. Transplantation. 1998;66:1313-1316.
9. Hanto DW, Whiting JF, Valente JF. Transplantation of the liver and intestine. In: Norton JA, Bollinger RR, Chang AE, et al, eds. Surgery: Scientific Basis and Current Practice, New York, NY: Springer-Verlag Inc; 2000:1473-1508.
10. 2003 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1993-2002. Richmond, Va; Rockville, Md: UNOS and the Division of Transplantation, Bureau of Health Resources and Services Administration, US Dept of Health and Human Services; 2003. In press.
11. Organ Procurement and Transplantation Network. Policy 3.6 Allocation of Livers. Available at: http://www.optn.org/policiesandbylaws/policies/docs/policy_8.doc. Accessed March 18, 2003.
12. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34.
13. Kim W, Brown R, Terrault N, El-Serag H. Burden of liver disease in the United States. Hepatology. 2002;36:227-242.
14. Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003;9:S10-S13.
15. Schafer DF, Shaw BW. Fulminant hepatic failure and orthotopic liver transplantation. Semin Liver Dis. 1989;9:189-194.
16. Lidofsky SD, Bass NM, Prager MC, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology. 1992;16:1-7.
17. Ramsay MAE, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg. 1997;3:494-500.
18. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
19. Karman JF, Sileri P, Kamuda D, et al. Risk factors for failure to meet listing requirements in liver transplant candidates with alcoholic cirrhosis. Transplantation. 2001;71:1210-1213.
20. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation. 2003;75:425-429.
21. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871.
22. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
23. Merion RM, Wolfe RA, Dykstra D, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003;9:12-18.
24. McHutchinson JG, Gordon SC, Schiff ER, et al, for the Hepatitis Intervention Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
25. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
26. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002;36:S185-S194.
27. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(5 suppl 1):S3-S20.
28. Poynard T, McHutchison J, Manns M, et al. Impact of pegyiated interferon alfa 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.
29. Everson GT, Trotter JF, Kugelmas M. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating-dose regimen) [abstract]. Hepatology. 2002;36:297A.
30. Eckhauser FE, Raper SE, Turcott JG. Cirrhosis and portal hypertension. In: Greenfield LJ, Mulholland M, Oldham KT, Zelenock GB, Lillemoe KD, eds. Surgery: Scientific Principles and Practice. Philadelphia, Pa: Lippincott-Raven; 1997:972-1008.
31. Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl. 2003;9:207-217.
32. Rickkers LF. The changing spectrum of treatment for variceal hemorrhage. Ann Surg. 1998;228:536-546.
33. Orloff MJ, Orloff MS, Orloff SL, Rambotti M, Girard B. Three decades of experience with emergency portacaval shunt for acutely bleeding esophageal varices in 400 unselected patients with cirrhosis of the liver. J Am Coll Surg. 1995;180:257-272.
34. Zacks SL, Sandler RS, Biddle AK, Mauro MA, Brown RS Jr. Decision-analysis of transjugular intrahepatic portosystemic shunt versus distal splenorenal shunt for portal hypertension. Hepatology, 1999;29:1399-1405.
35. Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590-597.
36. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:651-655.
37. Tanaka H, Hiyama T, Tsukuma H, et al. Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical estimations from cross-sectional data. Jpn J Cancer Res. 1994;85:485-490.
38. Curley SA, Isso R, Gallipoli A, de Bellis M, Cremona F, Parisi V. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg. 1995;222:375-383.
39. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47-53.
40. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology. 1994;20:33S-40S.
41. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218:145-151.
42. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
43. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
44. Fontana RJ, Hamidulla H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165-1174.
45. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right lobe from a living donor. N Engl J Med. 2002;346:1074-1082.
46. Umeshita K, Fujiwara K, Kiyosawa K, et al. Operative morbidity of living liver donors in Japan. Lancet. 2003;362:687-690.
47. Lo CM. Complications and long-term outcome of living liver donors: a survey of 1,508 cases in five Asian centers. Transplantation. 2003;75:S12-S15.
48. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology. 1994;20:829-838.
49. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002;8:132-142.
50. Kahan BD, Cardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72:1181-1193.
51. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638-645.
52. Pirsch JD, Kalayoglu M, Hafez GR, D'Alessandro AM, Sollinger HW, Belzer FO. Evidence that the vanishing duct syndrome is vanishing. Transplantation. 1990;49:1015-1018.
53. Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med. 1998;338:1741-1751.
54. Whiting JF, Rossi SJ, Hanto DW. Infectious complications after OKT3 induction in liver transplantation. Liver Transpl Surg. 1997;3:563-570.
55. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:729-737.
56. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety or oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet. 1997;350:1729-1733.
57. Davidson BR, Gibson M, Dick R, Burroughs A, Rolles K. Incidence, risk factors, management and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation. 1994;57:1174-1177.
58. Vallera RA, Cotton PB, Clavien PA. Biliary reconstruction for liver transplantation and management of biliary complications: overview and survey of current practices in the United States. Liver Transpl Surg. 1995;1:143-152.
59. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384-394.
60. Chariton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001;1:197-203.
61. Rosen JR. Hepatitis C in the liver transplant recipient: current understanding and treatment. Microbes Infect. 2002;4:1253-1258.
62. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34.
63. Forman L, Lewis J. Association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.
64. Lake JR. Role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 2003;9:S63-S66.
65. Braun M, Vierling JM. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl. 2003;9:S79-S89.
66. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-355.
67. Moore KA, Jones RM, Burrows GD. Quality of life and cognitive function of liver transplant patients: a prospective study. Liver Transpl. 2000;6:633-642.
68. Levy MF, Jennings L, Abouljoud MS, et al. Quality of life improvements at one, two, and five years after liver transplantation. Transplantation. 1995;59:515-518.
69. Bucuvalas JC, Britto M, Krug S, et al. Health-related quality of life in pediatric liver transplant recipients: a single-center study. Liver Transpl. 2003;9:62-71.
70. Lewis MB, Howdle PD. Cognitive dysfunction and health-related quality of life in long-term liver transplant survivors. Liver Transpl. 2003;9:1145-1148
71. Fox IJ, Roy Chowdhury J, Kaufman SS, et al. Treatment of the Crigler-Najjar Syndrome Type I with hepatocyte transplantation. N Engl J Med. 1998;338:1422-1426.